Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features�…

Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this�…

Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer management.
However, molecular determinants of response to ICIs remain incompletely understood�…

Despite progress in immunotherapy, identifying patients that respond has remained a
challenge. Through analysis of whole-exome and targeted sequence data from 5,449�…

Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell
lung cancer (NSCLC). However, only one-quarter of patients benefit from these new�…

Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…

Objectives Treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
blockade (ICB) has resulted in striking clinical responses, but only in a subset of patients�…

Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…

Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint
inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of�…

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…